If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Chondroitin Sulphate Effective in Patients With Concomitant Knee Osteoarthritis and Psoriasis: Presented at EULAR By Bruce Sylvester COPENHAGEN, Denmark -- June 15, 2007 -- Treatment of knee osteoarthritis with chondroitin sulphate (Condrosan) in patients with concomitant psoriasis shows efficacy for both conditions, researchers reported here at the 10th Annual Congress of the European League Against Rheumatism (EULAR). “The findings of this clinical trial confirm the efficacy and safety of chondroitin sulphate with symptomatic knee osteoarthritis, reducing pain and improving physical function and quality of life in patients with knee osteoarthritis,” said Ingrid Moller, MD, Instituto Poal de Reumatologia, Barcelona, Spain, on June 12. “The use of chondroitin sulphate could represent special benefit in patients with both pathologies since [nonsteroidal anti-inflammatory drugs] have been reported to exacerbate preexisting psoriasis,” she added. The study included 129 patients with knee osteoarthritis (American College of Rheumatology criteria, radiological Kellgren-Lawrence score 1-3, knee pain with Huskisson’s Visual Analogue Scale [VAS] >=30 mm) and psoriasis (Psoriasis Area and Severity Index [PASI] >=5). Patients were randomised to receive chondroitin sulphate 800 mg or placebo once daily for 3 months. The primary endpoints in regard to efficacy were changes in VAS and PASI scores. Both study groups had moderate to severe knee osteoarthritis and plaque psoriasis at baseline. At 3 months, chondroitin sulphate showed greater improvement in VAS than placebo, with a mean decrease of -26.9 +- 24.8 versus -14.2 +- 20.8 mm (P < .01). Compared with placebo, treatment with chondroitin sulphate resulted in improved physical function, with a decrease in the Lequesne’s index (-4.8 +- 3.4 vs -3.3 +- 3.5; P < .05), and a reduction in the number of patients using acetaminophen (43% vs 64%; P < .05). Patients achieved a mean 33% decrease in PASI after 3 months of treatment, but the change was not statistically significant compared with placebo. Analysis of the body areas affected with psoriatic lesions showed that chondroitin sulphate treatment significantly improved plantar psoriasis after 3 months compared with placebo (86.7% vs 26.7%; P < .05). Treatment with chondroitin sulphate also improved quality of life in some subscales of the Short-Form survey with 36 questions (both SF-36) and the Dermatology Life Quality Index. Both treatment groups were very tolerable to treatment. Psoriatic flares did not increase after treatment. The infrequent adverse events were evenly distributed among the study groups. [Presentation title: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial on the Effects of Chondroitin Sulphate in Patients With Knee Osteoarthritis and Psoriasis. Abstract THU0361]
|
